Drug Profile
Fentanyl controlled-release - Valerio Therapeutics
Alternative Names: BA-041; Fentanyl LauriadLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator BioAlliance Pharma
- Developer Valerio Therapeutics
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer pain
Highest Development Phases
- Discontinued Cancer pain
Most Recent Events
- 03 Sep 2014 Discontinued - Phase-I/II for Cancer pain (In volunteers) in France (Buccal)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 07 Oct 2010 Fentanyl controlled-release - BioAlliance Pharma is available for licensing as of 07 Oct 2010. www.bioalliancepharma.com